Inhibitory effects of Mycoepoxydiene on macrophage foam cell formation and atherosclerosis in ApoE-deficient mice
© Xia et al. 2015
Received: 25 March 2015
Accepted: 20 May 2015
Published: 26 May 2015
Mycoepoxydiene (MED) is a polyketide that can be isolated from a marine fungus and is associated with various activities, including antitumor and anti-inflammatory functions. However, its effects on atherosclerosis remain unknown. Macrophage-derived foam cells play crucial roles in the initiation and progression of atherosclerotic plaques. In this study, we investigated the effects of MED on oxidized low-density lipoprotein (ox-LDL)-induced macrophage foam cell formation and activation, and on high fat diet (HFD)-induced atherosclerosis in ApoE-deficient (ApoE −/− ) mice.
Our findings show that MED could significantly inhibit ox-LDL-induced macrophage foam cell formation and suppress the expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), which is a receptor for ox-LDL. Additionally, MED could significantly inhibit the secretion of proinflammatory cytokines, such as tumor necrosis factor (TNF-α), interleukin (IL)-6, and IL-1β. Mechanistically, MED inhibited NF-κB activation by blocking IκB-α degradation and reducing NF-κB DNA binding activity. Moreover, MED dramatically reduced the occurrence of HFD-induced atherosclerotic lesions in ApoE −/− mice.
Our study shows that MED can inhibit macrophage foam cell formation and activation by inhibiting NF-κB activation, thereby protecting ApoE −/− mice from HFD-induced atherosclerosis. Our findings suggest that MED might be a potential lead compound for the development of antiatherosclerotic therapeutics.
Atherosclerosis, a chronic inflammatory disease that is characterized by the accumulation of lipids and fibrous elements that result from interactions between vascular cells and inflammatory cells, is a leading cause of mortality in developed countries [1, 2]. Studies have shown that inflammation plays a critical role in all stages, from initiation through progression, and ultimately drives the thrombotic complications of atherosclerosis. Ox-LDL plays a critical role in triggering proinflammatory and pro-oxidant events in the initiation, propagation, and activation of atherosclerosis [3, 4]. Ox-LDL is taken up via the scavenger receptor expressed by macrophages, which turns macrophages into lipid-laden foam cells . Additionally, ox-LDL stimulates macrophages to release proinflammatory cytokines such as IL-1β and TNF-α .
LOX-1, which is a lectin-like receptor for ox-LDL in endothelial cells, smooth muscle cells, and macrophages [7–9], plays important roles in atherosclerosis development . The binding of ox-LDL to LOX-1 leads to ox-LDL uptake by macrophages and foam cell transformation . NF-κB, which is a downstream factor of LOX-1, is a pivotal transcription factor involved in atherosclerosis. NF-κB activation has been observed at different stages of atherosclerosis, from plaque formation to its destabilization and rupture [12, 13]. LOX-1 can be dynamically up-regulated by various proinflammatory, pro-oxidative, and mechanical stimuli [14–16]. Many antiatherosclerotic drugs, such as stains, exert their function at least in part via direct or indirect down-regulation of LOX-1 expression [17, 18].
Mycoepoxydiene (MED) is a novel polyketide that can be isolated from the marine fungus Diaporhte sp. (D.sp.) HLY-1 and was discovered in submerged rotten leaves of Kandelia candel in a mangrove forest in Fujian Province, China . It contains an α, β-unsaturated-lactone moiety and an oxygen-bridged cyclooctadiene core . Previous studies have shown that MED could exert antimicrobial and antitumor activities [19, 21]. Recently, we have showed that MED could inhibit LPS-induced inflammatory responses, ovariectomy-induced osteoporosis, and allergic responses in mice [22–24]. In macrophages, MED can significantly inhibit the LPS-induced expression of proinflammatory mediators, such as TNF-α, IL-6, IL-1β and nitric oxide (NO) through blocking the activation of both NF-κB and MAPK pathways . In mast cells, MED can significantly suppress antigen-stimulated degranulation and cytokine production by blocking the MAPK pathways. Because MED displays an anti-inflammatory activity, we wanted to determine whether it could inhibit atherosclerosis, which is related to the inflammatory response [25–27]. Herein, we show that MED can inhibit foam cell formation and cytokine production induced by ox-LDL in macrophages and protect ApoE −/− mice from atherosclerosis by blocking the NF-κB signaling.
MED significantly suppresses macrophage foam cell formation
MED inhibits ox-LDL-induced LOX-1 expression in macrophages
MED can suppress proinflammatory cytokine expression in macrophages induced by ox-LDL
MED inhibits ox-LDL induced activation of NF-κB signaling in macrophages
MED effectively reduces atherosclerotic lesions in ApoE−/− mice
Atherosclerosis is considered a type of chronic inflammation. The differentiation of macrophages to lipid-laden foam cells is a pivotal process in the development of the atherosclerosis . The transformation of foam cells can be attributed to the dysregulated uptake of modified LDL by macrophages [32, 33]. Ox-LDL is a critical factor in the initiation and progression of atherosclerosis, especially for foam cell formation. It is thought that uptake of ox-LDL by macrophage scavenger receptors is largely responsible for disease progression. As a receptor for ox-LDL, LOX-1 accumulates in human and animal atherosclerotic lesions in vivo . It has been shown that LOX-1 functions as a proinflammatory adhesion molecule in leukocytes and platelets . LOX-1 affects several inflammatory stages of atherosclerosis, such as macrophage foam cell formation and activation . It has been reported that the deletion of LOX-1 reduces atherogenesis in LDLR-knockout mice that are fed a high cholesterol diet , thus highlighting the important role of LOX-1 in atherosclerosis. In our present study, MED could significantly inhibit RAW 264.7 cells transformation into foam cells and LOX-1 expression induced by ox-LDL, which indicated that the suppression of LOX-1 expression by MED contributes to its inhibitory effects on macrophage foam cell formation.
It has been shown that LOX-1 is involved in inflammatory reactions and is an important mediator of inflammation . Macrophages produce abundant amounts of pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, to promote atherosclerosis. Herein, we have shown that MED can significantly inhibit the ox-LDL-induced expression of TNF-α, IL-6, and IL-1β both in RAW264.7 cells and in plaque lesion areas, which suggests that MED can suppress inflammatory responses in atherosclerosis.
NF-κB is a transcription factor involved in several inflammatory diseases, including atherosclerosis. The activation of NF-κB has been observed at different stages of atherosclerosis . The binding of ox-LDL to LOX-1 can activate NF-κB signaling, thus leading to enhanced macrophage foam cell formation and proinflammatory cytokine production. Our data show that MED could significantly inhibit ox-LDL/LOX-1-induced activation of NF-κB signaling, which suggests that MED inhibits macrophage foam cell formation and activation at least in part by blocking NF-κB signaling.
The most significant finding of this current study is that MED could dramatically suppress atherosclerosis in ApoE −/− mice fed a high fat diet. In addition to inhibiting inflammation and foam cell formation, we found that MED could significantly reduce the levels of blood fats, such as total triglyceride, total cholesterol, high-density lipoprotein, and low-density lipoprotein in mice (Additional file 3: Figure S3). These features might all contribute to the anti-atherogenic activity of MED. Therefore, MED exhibits the anti-atherogenic activity both in vitro and in vivo, which suggests that MED might represent a novel drug candidate for the effective treatment of atherosclerosis.
Collectively, our results demonstrate that MED, a novel marine microbial compound, can inhibit macrophage foam cell formation and activation in vitro and suppress atherosclerosis in ApoE −/− mice, at least in part by inhibiting NF-κB activation. Our findings suggest that MED represents is a potential lead compound for the development of novel anti-atherosclerotic drugs.
Materials and methods
MED was isolated from the fermentation broth of D. sp. HLY-1, as previously described . The identity of MED was confirmed by HRMS and 1H and 13C NMR analysis, and the purity of MED exceeded 95.7 % according to HPLC analysis. MED was dissolved in dimethylsulfoxide (DMSO) and stored at −20 °C. DMSO, MTT, oil red O, and anti-β-actin antibody were obtained from Sigma-Aldrich (Sigma, St. Louis, MO, USA); IL-1β ELISA kit, IL-6 ELISA kit, and TNF-α ELISA kit were obtained from eBioscience (eBioscience, SanDiego, CA, USA); DMEM was purchased from Gibco (Gibco, Grand Island,NY, USA); fetal bovine serum (FBS) was obtained from Hyclone (Thermo Scientific, IL, USA); Ox-LDL was purchased from Unionbiol (Beijing, China); anti-IκB-α antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA); antibodies against p65 and PARP were purchased from Cell Signaling Technology (Danvers, MA, USA); antibody against LOX-1 was obtained from R&D systems (Minneapolis, MN, USA); high-fat diet was produced by Vital River Laboratories (Beijing, China) according to the formula from Harlan (TD.88137).
Murine macrophage cell RAW 264.7 cells were purchased from the American Type Cell Culture Collection. Cells were cultured in DMEM supplemented with 10 % fetal bovine serum (FBS).
The cytotoxicity of MED was analyzed using a MTT assay. A total of 7 × 103 cells/well were seeded into a 96-well plate. After incubation with MED for 24 h, 10 μl MTT (5 mg/ml, Sigma) was added to each well. Plates were incubated for 4 h before adding of 100 μl lysis buffer (10 % SDS in 0.01 M HCl). Absorbance was measured at 560 nm using a microplate reader.
Western blot analysis
Lysates for western blot analysis were prepared from cells and aortic tissues. A total of 30 μg protein lysates of each sample were subjected to SDS-PAGE and transferred onto nitrocellulose membranes. Blots were incubated with appropriate specific primary antibodies overnight at 4 °C. After washing three times for 15 min each with TBST (TBS + 0.1 % Tween20), blots were incubated with horseradish-peroxidase-conjugated secondary antibody (Pierce, Rockford, IL, USA) and visualized by chemiluminescence. Band densities were quantified by densitometry using the Scion Image software and were normalized to the β-actin and PARP levels.
Quantitative real-time PCR
Total RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer’s instructions. The cDNA was synthesized from 2 μg total RNA using MMLV transcriptase (ToYoBo, Shanghai, China) with random primers, real-time PCR was performed using SYBR Premix ExTaq (TaKaRa, Dalian, China). Quantification was normalized to the amount of endogenous GAPDH.
Cells were seeded in 96-well plates 24 h prior to ox-LDL and MED treatment, and the concentrations of TNF-α, IL-6, and IL-1β were determined using ELISA kits (eBioscience, San Diego, CA) according to the manufacturer’s instructions.
High-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride (TG), and total cholesterol (TC)
Mice were euthanized and blood was collected. HDL, LDL, TG, and TC were measured using ELISA kits according to the manufacturer’s instructions.
Nuclear protein extraction
After ox-LDL and MED treatments, cells were collected and then Buffer A (10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, and 0.5 mM PMSF) was added. After incubation on ice for 20 min, cells were suspended in Buffer A with 2.5 % NP- 40, vortexed for 10 s and then centrifuged at 12,000 × g for 5 min at 4 °C. Supernatants were collected to detect cytoplasmic proteins. Buffer B (20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM DTT, and 1 mM PMSF) was used to resuspend the precipitates, and the suspension was vortexed for 25 min at 4 °C and then centrifuged at 12,000 × g for 5 min at 4 °C. Supernatants were collected as nuclear extracts, and the protein concentrations were measured using the Bradford protein assay (Bio-Rad, Hercules, CA).
Electrophoretic mobility shift assay
A total of 10 μg nuclear extract was incubated with 20 nM biotin-labeled double- stranded oligonucleotide probes for 20 min at room temperature, and then were separated on a non-denaturing 6 % (w/v) polyacrylamide gel. The biotin-labeled oligonucleotide probes (NF-κB: 5′ -AGT TGA GGG GAC TTT CCC AGG C-3′, 3′ -TCA ACT CCC CTG AAA GGG TCC G-5′) were transferred from the polyacrylamide gel onto a nylon membrane. Bands were detected with a LightShift chemiluminescent EMSA kit (Pierce, Rockford, IL) according to the manufacturer’s instruction.
High-fat diet-induced atherosclerosis in ApoE−/− mice
Eight-week-old ApoE −/− mice were fed a high-fat diet for 12 weeks to induce atherosclerosis. All experiments were approved by the Animal Care and Use Committee of Xiamen University (Protocol Number: XMULAC 20120001). Every effort was made to reduce animal suffering.
Atherosclerotic lesion analysis
Mice were euthanized and their hearts and aortas were isolated. The degree of atherosclerosis was assessed by determining lesion sizes on both pinned open aortas and serial cross-sections through the aortic root as previously described but with some modification [38–40]. The aorta was opened longitudinally along the ventral midline from the iliac arteries to the aortic root. After the branching vessels were treated, the aorta was pinned out flat on a black wax surface. Lesions were treated with 70 % ethanol and then stained with Sudan IV for 15 min, destained with 80 % ethanol, and then washed with PBS. Aortic images were analyzed using the Adobe Photoshop software; data are reported as the percentage of the aortic surface covered by lesions.
Data were collected from several independent experiments, with three replicates per experiment. All data were analyzed by one-way Anova with post-Tukey’s post-test with the SPSS 16.0 software package: p < 0.05 and p < 0.01 were considered to indicate statistically significant differences. Bars in the graph represent standard deviation (S.D.).
This work was supported by grants from the Natural Science Foundation of China (81270277), and the Natural Science Foundation of Fujian Province of China (2010 J06014).
- Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.PubMedView ArticleGoogle Scholar
- Zhao Y, Liu Y, Zhang W, Xue J, Wu YZ, Xu W, et al. WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. Eur J Pharmacol. 2010;649(1–3):285–92. doi:10.1016/j.ejphar.2010.09.027.PubMedView ArticleGoogle Scholar
- Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997;272(34):20963–6.PubMedView ArticleGoogle Scholar
- Robbesyn F, Salvayre R, Negre-Salvayre A. Dual role of oxidized LDL on the NF-kappaB signaling pathway. Free Radic Res. 2004;38(6):541–51.PubMedView ArticleGoogle Scholar
- Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95. doi:10.1056/NEJMra043430.PubMedView ArticleGoogle Scholar
- Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23(4):656–60. doi:10.1161/01.ATV.0000064374.15232.C3.PubMedView ArticleGoogle Scholar
- Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386(6620):73–7. doi:10.1038/386073a0.PubMedView ArticleGoogle Scholar
- Aoyama T, Chen M, Fujiwara H, Masaki T, Sawamura T. LOX-1 mediates lysophosphatidylcholine-induced oxidized LDL uptake in smooth muscle cells. FEBS Lett. 2000;467(2–3):217–20.PubMedView ArticleGoogle Scholar
- Li L, Sawamura T, Renier G. Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res. 2004;94(7):892–901. doi:10.1161/01.RES.0000124920.09738.26.PubMedView ArticleGoogle Scholar
- Shi X, Niimi S, Ohtani T, Machida S. Characterization of residues and sequences of the carbohydrate recognition domain required for cell surface localization and ligand binding of human lectin-like oxidized LDL receptor. J Cell Sci. 2001;114(Pt 7):1273–82.PubMedGoogle Scholar
- Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation. 1999;99(24):3110–7.PubMedView ArticleGoogle Scholar
- Liu H, Jiang D, Zhang S, Ou B. Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice. Cardiovasc Drugs Ther. 2010;24(1):17–24. doi:10.1007/s10557-009-6210-7.PubMedView ArticleGoogle Scholar
- Pamukcu B, Lip GY, Shantsila E. The nuclear factor–kappa B pathway in atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. Thromb Res. 2011;128(2):117–23. doi:10.1016/j.thromres.2011.03.025.PubMedView ArticleGoogle Scholar
- Li D, Mehta JL. Intracellular signaling of LOX-1 in endothelial cell apoptosis. Circ Res. 2009;104(5):566–8. doi:10.1161/CIRCRESAHA.109.194209.PubMedView ArticleGoogle Scholar
- Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther. 2002;95(1):89–100.PubMedView ArticleGoogle Scholar
- Ogura S, Kakino A, Sato Y, Fujita Y, Iwamoto S, Otsui K, et al. Lox-1: the multifunctional receptor underlying cardiovascular dysfunction. Circ J. 2009;73(11):1993–9.PubMedView ArticleGoogle Scholar
- Li DY, Chen HJ, Mehta JL. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res. 2001;52(1):130–5.PubMedView ArticleGoogle Scholar
- Hofnagel O, Luechtenborg B, Eschert H, Weissen-Plenz G, Severs NJ, Robenek H. Pravastatin inhibits expression of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in Watanabe heritable hyperlipidemic rabbits: a new pleiotropic effect of statins. Arterioscler Thromb Vasc Biol. 2006;26(3):604–10. doi:10.1161/01.ATV.0000201073.45862.8b.PubMedView ArticleGoogle Scholar
- Lin X, Huang Y, Fang M, Wang J, Zheng Z, Su W. Cytotoxic and antimicrobial metabolites from marine lignicolous fungi, Diaporthe sp. FEMS Microbiol Lett. 2005;251(1):53–8. doi:10.1016/j.femsle.2005.07.025.PubMedView ArticleGoogle Scholar
- Takao K, Watanabe G, Yasui H, Tadano K. Total synthesis of (+/−)-mycoepoxydiene, a novel fungal metabolite having an oxygen-bridged cyclooctadiene skeleton. Org Lett. 2002;4(17):2941–3.PubMedView ArticleGoogle Scholar
- Wang J, Zhao B, Zhang W, Wu X, Wang R, Huang Y, et al. Mycoepoxydiene, a fungal polyketide, induces cell cycle arrest at the G2/M phase and apoptosis in HeLa cells. Bioorg Med Chem Lett. 2010;20(23):7054–8. doi:10.1016/j.bmcl.2010.09.105.PubMedView ArticleGoogle Scholar
- Chen Q, Chen T, Li W, Zhang W, Zhu J, Li Y, et al. Mycoepoxydiene inhibits lipopolysaccharide-induced inflammatory responses through the suppression of TRAF6 polyubiquitination [corrected]. PLoS One. 2012;7(9):e44890. doi:10.1371/journal.pone.0044890.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhu J, Chen Q, Xia X, Mo P, Shen Y, Yu C. Mycoepoxydiene suppresses RANKL-induced osteoclast differentiation and reduces ovariectomy-induced bone loss in mice. Appl Microbiol Biotechnol. 2013;97(2):767–74. doi:10.1007/s00253-012-4146-5.PubMedView ArticleGoogle Scholar
- Xia XC, Chen Q, Liu K, Mo PL, Zhu JW, Zhuang MQ, et al. Mycoepoxydiene inhibits antigen-stimulated activation of mast cells and suppresses IgE-mediated anaphylaxis in mice. Int Immunopharmacol. 2013;17(2):336–41. doi:10.1016/j.intimp.2013.06.029.PubMedView ArticleGoogle Scholar
- de Vries-van der Weij J, Toet K, Zadelaar S, Wielinga PY, Kleemann R, Rensen PC, et al. Anti-inflammatory salicylate beneficially modulates pre-existing atherosclerosis through quenching of NF-kappaB activity and lowering of cholesterol. Atherosclerosis. 2010;213(1):241–6. doi:10.1016/j.atherosclerosis.2010.09.006.PubMedView ArticleGoogle Scholar
- van Diepen JA, Berbee JF, Havekes LM, Rensen PC. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis. 2013;228(2):306–15. doi:10.1016/j.atherosclerosis.2013.02.028.PubMedView ArticleGoogle Scholar
- Mendez-Fernandez YV, Stevenson BG, Diehl CJ, Braun NA, Wade NS, Covarrubias R, et al. The inhibitory FcgammaRIIb modulates the inflammatory response and influences atherosclerosis in male apoE(−/−) mice. Atherosclerosis. 2011;214(1):73–80. doi:10.1016/j.atherosclerosis.2010.10.018.PubMed CentralPubMedView ArticleGoogle Scholar
- Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol. 2005;3(1):63–8.PubMedView ArticleGoogle Scholar
- Xu S, Liu Z, Huang Y, Le K, Tang F, Huang H, et al. Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-kappaB activation. Transl Res. 2012;160(2):114–24. doi:10.1016/j.trsl.2012.01.008.PubMedView ArticleGoogle Scholar
- Zhou J, Moller J, Ritskes-Hoitinga M, Larsen ML, Austin RC, Falk E. Effects of vitamin supplementation and hyperhomocysteinemia on atherosclerosis in apoE-deficient mice. Atherosclerosis. 2003;168(2):255–62.PubMedView ArticleGoogle Scholar
- Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–41. doi:10.1038/35025203.PubMed CentralPubMedView ArticleGoogle Scholar
- Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91(9):2488–96.PubMedView ArticleGoogle Scholar
- Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362(6423):801–9. doi:10.1038/362801a0.PubMedView ArticleGoogle Scholar
- Chen H, Li D, Sawamura T, Inoue K, Mehta JL. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun. 2000;276(3):1100–4. doi:10.1006/bbrc.2000.3532.PubMedView ArticleGoogle Scholar
- Honjo M, Nakamura K, Yamashiro K, Kiryu J, Tanihara H, McEvoy LM, et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci U S A. 2003;100(3):1274–9. doi:10.1073/pnas.0337528100.PubMed CentralPubMedView ArticleGoogle Scholar
- Mehta JL, Sanada N, Hu CP, Chen J, Dandapat A, Sugawara F, et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res. 2007;100(11):1634–42. doi:10.1161/CIRCRESAHA.107.149724.PubMedView ArticleGoogle Scholar
- Wu Z, Sawamura T, Kurdowska AK, Ji HL, Idell S, Fu J. LOX-1 deletion improves neutrophil responses, enhances bacterial clearance, and reduces lung injury in a murine polymicrobial sepsis model. Infect Immun. 2011;79(7):2865–70. doi:10.1128/IAI.01317-10.PubMed CentralPubMedView ArticleGoogle Scholar
- Seimon TA, Wang Y, Han S, Senokuchi T, Schrijvers DM, Kuriakose G, et al. Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest. 2009;119(4):886–98. doi:10.1172/JCI37262.PubMed CentralPubMedGoogle Scholar
- Sekiya M, Osuga J, Nagashima S, Ohshiro T, Igarashi M, Okazaki H, et al. Ablation of neutral cholesterol ester hydrolase 1 accelerates atherosclerosis. Cell Metab. 2009;10(3):219–28. doi:10.1016/j.cmet.2009.08.004.PubMedView ArticleGoogle Scholar
- Thorp E, Li G, Seimon TA, Kuriakose G, Ron D, Tabas I. Reduced apoptosis and plaque necrosis in advanced atherosclerotic lesions of Apoe−/− and Ldlr−/− mice lacking CHOP. Cell Metab. 2009;9(5):474–81. doi:10.1016/j.cmet.2009.03.003.PubMed CentralPubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.